

IACH 2021 Program
All timing in CEST

Friday, September 24, 2021	
12:45-13:00	Welcome: <u>Mohamad Mohty</u> , France & <u>Arnon Nagler</u> , Israel
13:00-14:50	Opening Session: State of the art therapy in ...
13:00-13:20	CLL: <i>TBA</i>
13:20-13:40	CML: <i>TBA</i>
13:40-14:00	Hodgkin lymphoma: <u>Ali Bazarbachi</u> , Lebanon
14:00-14:20	Mantle cell lymphoma: <i>TBA</i>
14:20-14:50	Panel Discussion
14:50-15:00	<i>Break</i>
15:00-16:50	Session 1: Immunotherapy
15:00-15:20	Immune modulation prior and post HSCT for AML: <u>Gesine Bug</u> , Germany
15:20-15:40	TCR Engineering: <i>TBA</i>
15:40-16:00	Anti-virus CTLs: <i>TBA</i>
16:00-16:20	Gamma/delta T cells: <u>Jurgen Kuball</u> , Netherlands
16:20-16:50	Panel Discussion
16:50-17:00	<i>Break</i>
17:00-18:50	Session 2: Transplant indications in ...
17:00-17:20	AML: <u>Arnon Nagler</u> , Israel
17:20-17:40	ALL: <i>TBA</i>
17:40-18:00	MF: <u>Ibrahim Yakoub-Agha</u> , France
18:00-18:20	MDS: <u>Corey Cutler</u> , USA
18:20-18:50	Panel Discussion
18:50-19:00	<i>Break</i>
19:00-19:30	ALL – Progress in research and Therapy in 2021: <u>Hagop Kantarjian</u> , USA

Saturday, September 25, 2021	
09:00-11:20	Session 3: Advances in transplant complications
09:00-09:20	Acute GVHD: <u>Iskra Pusic</u> , USA
09:20-09:40	Chronic GVHD: <u>Zinaida Perić</u> , Croatia
09:40-10:00	CMV infection at the era of letermovir: <u>Bipin Savani</u> , USA
10:00-10:20	Endothelium-related complications: <u>Selim Corbacioglu</u> , Germany
10:20-10:40	EBV-PTLD: <u>Rafael de la Cámara</u> , Spain
10:40-11:20	Panel Discussion
11:20-11:30	<i>Break</i>
11:30-13:20	Session 4: Advances in AML therapy
11:30-11:50	The case for CPX-351: <u>Pau Montesinos</u> , Spain
11:50-12:10	The case for oral azacytidine: <u>Amer Zeidan</u> , USA
12:10-12:30	The case for venetoclax: <i>TBA</i>
12:30-12:50	The case for Flt3 inhibitors: <i>TBA</i>
12:50-13:20	Panel Discussion
13:20-13:30	<i>Break</i>
13:30-15:00	Industry Symposium
15:00-15:30	Industry Meet the Exper Session (<i>during the break</i>)
15:00-15:30	<i>Break</i>

15:30-17:20	Session 5: Advances in rare entities
15:30-15:50	BPDCN: <u>Naveen Pemmaraju, USA</u>
15:50-16:10	Mastocytosis: <i>TBA</i>
16:10-16:30	Aplastic anemia: <i>TBA</i>
16:30-16:50	Waldenstrom disease: <i>TBA</i>
16:50-17:20	Panel Discussion
17:20-17:30	<i>Break</i>
17:30-19:30	Session 6: Bispecific antibodies and antibody-drug conjugates in ...
17:30-17:50	Lymphoma: <u>Gilles Salles, USA</u>
17:50-18:10	Myeloma: <u>Salomon Manier, France</u>
18:10-18:30	AML: <i>TBA</i>
18:30-18:50	ALL: <u>Eolia Brissot, France</u>
18:50-19:30	Panel Discussion

Sunday, September 26, 2021

09:00-10:50	Session 7: State of the art in HSCT
09:00-09:20	Optimizing stem cell collection: <u>Christian Chabannon, France</u>
09:20-09:40	PtCy for GVHD prophylaxis: <u>Didier Blaise, France</u>
09:40-10:00	Optimal choice of donor: <u>Annalisa Ruggeri, Italy</u>
10:00-10:20	Bloodless HSCT: <u>Bhagirathbhai Dholaria, USA</u>
10:20-10:50	Panel Discussion
10:50-11:00	<i>Break</i>
11:00-12:00	Industry Symposium
12:00-13:50	Session 8: CAR T cells in ...
12:00-12:20	ALL: <u>Jordan Gauthier, USA</u>
12:20-12:40	CLL: <u>Mohamed Kharfan-Dabaja, USA</u>
12:40-13:00	Myeloma: <u>Mohamad Mohty, France</u>
13:00-13:20	Lymphoma: <u>Anna Sureda, Spain</u>
13:20-13:50	Panel Discussion
13:50-14:00	<i>Break</i>
14:00-14:15	Closing Remarks: <u>Mohamad Mohty, France</u> & <u>Arnon Nagler, Israel</u>